Molecular expression of vascular endothelial growth factor, prokineticin receptor‑1 and other biomarkers in infiltrating canalicular carcinoma of the breast

Morales,Angélica; Morimoto,Sumiko; Vilchis,Felipe; Taniyama,Natsuko; Bautista,Claudia J.; Robles,Carlos; Bargalló,Enrique

doi:10.3892/ol.2016.4961

Molecular expression of vascular endothelial growth factor, prokineticin receptor‑1 and other biomarkers in infiltrating canalicular carcinoma of the breast

Authors:
- Angélica Morales
- Sumiko Morimoto
- Felipe Vilchis
- Natsuko Taniyama
- Claudia J. Bautista
- Carlos Robles
- Enrique Bargalló
View Affiliations

Affiliations: Department of Reproductive Biology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City 14080, Mexico, Department of Mammary Tumors, National Cancer Institute, Mexico City 14080, Mexico
Published online on: August 5, 2016 https://doi.org/10.3892/ol.2016.4961
Pages: 2720-2727

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular endothelial growth factor (VEGF) is important in the growth and metastasis of cancer cells. In 2001, another angiogenic factor, endocrine gland‑derived VEGF (EG‑VEGF), was characterized and sequenced. EG‑VEGF activity appears to be restricted to endothelial cells derived from endocrine glands. At the molecular level, its expression is regulated by hypoxia and steroid hormones. Although VEGF and EG‑VEGF are structurally different, they function in a coordinated fashion. Since the majority of mammary tumors are hormone‑dependent, it was hypothesized that EG‑VEGF would be expressed in these tumors, and therefore, represent a potential target for anti‑angiogenic therapy. The aim of the present study was to assess the expression of VEGF, EG‑VEGF and its receptor (prokineticin receptor‑1), as well as that of breast cancer resistant protein, estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, in 50 breast samples of infiltrating canalicular carcinoma (ICC) and their correlation with tumor staging. The samples were analyzed using reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry. Both angiogenic growth factors were identified in all samples. However, in 90% of the samples, the expression level of VEGF was significantly higher than that of EG‑VEGF (P=0.024). There was no association between the expression of VEGF, EG‑VEGF or its receptor with tumor stage. In ICC, the predominant angiogenic factor expressed was VEGF. The expression level of either factor was not correlated with the tumor‑node‑metastasis stage. Although ICC is derived from endothelial cells, EG‑VEGF expression was not the predominant angiogenic/growth factor in ICC.

View Figures

View References

1	Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar : PubMed/NCBI
2	Schneider BP and Miller KD: Angiogenesis of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
3	LeCouter J, Lin R and Ferrara N: The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. Cold Spring Harb Symp Quant Biol. 67:217–221. 2002. View Article : Google Scholar : PubMed/NCBI
4	Kaser A, Winklmayr M, Lepperdinger G and Kreil G: The AVIT protein family. Secreted cysteine-rich vertebrate proteins with diverse functions. EMBO Rep. 4:469–473. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zhou QY and Meidan R: Biological function of prokineticins. Results Probl Cell Differ. 46:181–199. 2008. View Article : Google Scholar : PubMed/NCBI
6	Keramidas M, Faudot C, Cibiel A, Feige JJ and Thomas M: Mitogenic functions of endocrine gland-derived vascular endothelial growth factor and Bombina variegata 8 on steroidogenic adrenocortical cells. J Endocrinol. 196:473–482. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kisliouk T, Levy N, Hurwitz A and Meidan R: Presence and regulation of endocrine gland vascular endothelial growth factor/prokineticin-1 and its receptors in ovarian cells. J Clin Endocrinol Metab. 88:3700–3707. 2003. View Article : Google Scholar : PubMed/NCBI
8	Fraser HM, Bell J, Wilson H, Taylor PD, Morgan K, Anderson RA and Duncan WC: Localization and quantification of cyclic changes in the expression of endocrine gland vascular endothelial growth factor in the human corpus luteum. J Clin Endocrinol Metab. 90:427–434. 2005. View Article : Google Scholar : PubMed/NCBI
9	Morales A, Morimoto S, Díaz L, Robles G and Díaz-Sánchez V: Endocrine gland-derived vascular endothelial growth factor in rat pancreas: Genetic expression and testosterone regulation. J Endocrinol. 197:309–314. 2008. View Article : Google Scholar : PubMed/NCBI
10	Nagano H, Goi T, Koneri K, Hirono Y, Katayama K and Yamaguchi A: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer. J Surg Oncol. 96:605–610. 2007. View Article : Google Scholar : PubMed/NCBI
11	PerrotApplanat M and Di Benedetto M: Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion. Cell Adh Migr. 6:547–553. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kassim SK, ElSalahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel-D and Khalifa A: Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 37:363–369. 2004. View Article : Google Scholar : PubMed/NCBI
13	DeSantis CE, Bray F, Ferlay J, LortetTieulent J, Anderson BO and Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 24:1495–1506. 2015. View Article : Google Scholar : PubMed/NCBI
14	Córdova JA, Hernández M, Ortiz ME, Lezana MA, López-Gatell H and Alpuche CM: Epidemiological profile of malignant tumors in Mexico. In: IEPSA. Mexico City. pp. 145–195. 2011;
15	Euhus D, Di Carlo PA and Khouri NF: Breast cancer screening. Surg Clin North Am. 95:991–1011. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li J, Chen Z, Su K and Zeng J: Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 8:8500–8505. 2015.PubMed/NCBI
18	Mao Q and Unadkat JD: Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J. 17:65–82. 2015. View Article : Google Scholar : PubMed/NCBI
19	Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH and van de Vijver MJ: Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 8:1068–1074. 2002.PubMed/NCBI
20	Glavinas H, Krajcsi P, Cserepes J and Sarkadi B: The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004. View Article : Google Scholar : PubMed/NCBI
21	Javam M, Audette MC, Iqbal M, Bloise E, Gibb W and Matthews SG: Effect of oxygen on multidrug resistance in term human placenta. Placenta. 35:324–330. 2014. View Article : Google Scholar : PubMed/NCBI
22	Vore M and Leggas M: Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 73:613–615. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D and Zhou G: Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat. 123:679–689. 2010. View Article : Google Scholar : PubMed/NCBI
24	Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR and Izquierdo MA: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol. 198:213–219. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD and Mao Q: Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol. 73:845–854. 2008. View Article : Google Scholar : PubMed/NCBI
26	Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C and Cowan KH: Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52:6175–6181. 1992.PubMed/NCBI
27	Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W and Rauschecker H: The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat. 25:235–245. 1993. View Article : Google Scholar : PubMed/NCBI
28	PanchukVoloshina N and Haugland RP, BishopStewart J, Bhalgat MK, Millard PJ, Mao F, Leung WY and Haugland RP: Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J Histochem Cytochem. 47:1179–1188. 1999. View Article : Google Scholar : PubMed/NCBI
29	Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol. 13:962–972. 2000. View Article : Google Scholar : PubMed/NCBI
30	Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, et al: Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 124:859–870. 2014. View Article : Google Scholar : PubMed/NCBI
31	Howlett AR and Bissell MJ: The influence of tissue microenvironment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithelial Cell Biol. 2:79–89. 1993.PubMed/NCBI
32	Obr AE and Edwards DP: The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol. 357:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
33	Shak S: Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 26(Suppl 12): 71–77. 1999.PubMed/NCBI
34	Schmadeka R, Harmon BE and Singh M: Triple-negative breast carcinoma: Current and emerging concepts. Am J Clin Pathol. 141:462–477. 2014. View Article : Google Scholar : PubMed/NCBI
35	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumors. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
36	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
37	Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J and Lewensohn R: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 20:1639–1646. 2009. View Article : Google Scholar : PubMed/NCBI
38	LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, DillardTelm L, Frantz G, Rangell L, DeGuzman L, Keller GA, et al: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 412:877–884. 2001. View Article : Google Scholar : PubMed/NCBI
39	Moitra K, Lou H and Dean M: Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 89:491–502. 2011. View Article : Google Scholar : PubMed/NCBI
40	Dankers AC, Sweep FC, Pertijs JC, Verweij V, van den Heuvel JJ, Koenderink JB, Russel FG and Masereeuw R: Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 349:551–563. 2012. View Article : Google Scholar : PubMed/NCBI
41	Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD and Beck WT: Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 64:1247–1251. 2004. View Article : Google Scholar : PubMed/NCBI
42	Imai Y, Ishikawa E, Asada S and Sugimoto Y: Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 65:596–604. 2005.PubMed/NCBI
43	Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, Margeta M and Tlsty TD: Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci USA. 110:4598–4603. 2013. View Article : Google Scholar : PubMed/NCBI
44	Dempke WC and Heinemann V: Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer. 45:1117–1128. 2009. View Article : Google Scholar : PubMed/NCBI
45	Mercurio AM, Lipscomb EA and Bachelder RE: Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia. 10:283–290. 2005. View Article : Google Scholar : PubMed/NCBI
46	Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI
47	Chan A: Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs. 69:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
48	BanysPaluchowski M, Schütz F, Ruckhäberle E, Krawczyk N and Fehm T: Metronomic chemotherapy for metastatic breast cancer - a systematic review of the literature. Geburtshilfe Frauenheilkd. 76:525–534. 2016. View Article : Google Scholar : PubMed/NCBI
49	Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K and Härkönen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 149:29–40. 1999. View Article : Google Scholar : PubMed/NCBI
50	Takei H, Lee ES and Jordan VC: In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer. 9:39–42. 2002. View Article : Google Scholar : PubMed/NCBI
51	Bogin L and Degani H: Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res. 62:1948–1951. 2002.PubMed/NCBI
52	Mirkin S, Wong BC and Archer DF: Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 84:485–491. 2005. View Article : Google Scholar : PubMed/NCBI
53	Mirkin S, Wong BC and Archer DF: Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells. Int J Gynecol Cancer. 16(Suppl 2): S560–S563. 2006. View Article : Google Scholar